PMID- 29229532
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20201123
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 820
DP  - 2018 Feb 5
TI  - Inflammation and renal fibrosis: Recent developments on key signaling molecules 
      as potential therapeutic targets.
PG  - 65-76
LID - S0014-2999(17)30800-2 [pii]
LID - 10.1016/j.ejphar.2017.12.016 [doi]
AB  - Chronic kidney disease (CKD) is a major public health issue. At the histological 
      level, renal fibrosis is the final common pathway of progressive kidney disease 
      irrespective of the initial injury. Considerable evidence now indicates that 
      renal inflammation plays a central role in the initiation and progression of CKD. 
      Some of the inflammatory signaling molecules involved in CKD include: monocyte 
      chemoattractant protein-1 (MCP-1), bradykinin B(1) receptor (B(1)R), nuclear 
      factor kappaB (NF-kappaB), tumor necrosis factor-alpha (TNFalpha), transforming growth factor beta 
      (TGF-beta), and platelet-derived growth factor (PDGF). Multiple antifibrotic 
      factors, such as interleukin-10 (IL-10), interferon-gamma (IFN-gamma), bone morphogenetic 
      protein-7 (BMP-7), hepatocyte growth factor (HGF) are also downregulated in CKD. 
      Therefore, restoration of the proper balance between pro- and antifibrotic 
      signaling pathways could serve as a guiding principle for the design of new 
      antifibrotic strategies that simultaneously target many pathways. The purpose of 
      this review is to summarize the existing body of knowledge regarding activation 
      of cytokine pathways and infiltration of inflammatory cells as a starting point 
      for developing novel antifibrotic therapies to prevent progression of CKD.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Lv, Wenshan
AU  - Lv W
AD  - Department of Pharmacology and Toxicology, University of Mississippi Medical 
      Center, Jackson, MS 39216, USA; Department of Endocrinology and Metabolism, the 
      Affiliated Hospital of Qingdao University, Qingdao 26003, China.
FAU - Booz, George W
AU  - Booz GW
AD  - Department of Pharmacology and Toxicology, University of Mississippi Medical 
      Center, Jackson, MS 39216, USA.
FAU - Wang, Yangang
AU  - Wang Y
AD  - Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao 
      University, Qingdao 26003, China.
FAU - Fan, Fan
AU  - Fan F
AD  - Department of Pharmacology and Toxicology, University of Mississippi Medical 
      Center, Jackson, MS 39216, USA.
FAU - Roman, Richard J
AU  - Roman RJ
AD  - Department of Pharmacology and Toxicology, University of Mississippi Medical 
      Center, Jackson, MS 39216, USA. Electronic address: rroman@umc.edu.
LA  - eng
GR  - R01 DK104184/DK/NIDDK NIH HHS/United States
GR  - R01 AG057842/AG/NIA NIH HHS/United States
GR  - R21 AG050049/AG/NIA NIH HHS/United States
GR  - P20 GM104357/GM/NIGMS NIH HHS/United States
GR  - R01 HL138685/HL/NHLBI NIH HHS/United States
GR  - R37 HL036279/HL/NHLBI NIH HHS/United States
GR  - R01 HL036279/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20171208
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
SB  - IM
MH  - Animals
MH  - Fibrosis
MH  - Humans
MH  - Inflammation/drug therapy/pathology
MH  - Kidney/*drug effects/*pathology
MH  - Molecular Targeted Therapy/*methods
MH  - Signal Transduction/drug effects
PMC - PMC6733417
MID - NIHMS928988
OTO - NOTNLM
OT  - Antifibrotic therapy
OT  - Chronic kidney disease
OT  - Cytokines
OT  - Inflammation
OT  - Renal fibrosis
EDAT- 2017/12/13 06:00
MHDA- 2018/08/07 06:00
PMCR- 2019/09/09
CRDT- 2017/12/13 06:00
PHST- 2017/09/29 00:00 [received]
PHST- 2017/12/07 00:00 [revised]
PHST- 2017/12/07 00:00 [accepted]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2019/09/09 00:00 [pmc-release]
AID - S0014-2999(17)30800-2 [pii]
AID - 10.1016/j.ejphar.2017.12.016 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2018 Feb 5;820:65-76. doi: 10.1016/j.ejphar.2017.12.016. Epub 
      2017 Dec 8.